BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32088858)

  • 1. Puzzle of highly pathogenic human coronaviruses (2019-nCoV).
    Li J; Liu W
    Protein Cell; 2020 Apr; 11(4):235-238. PubMed ID: 32088858
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on the 2019 novel coronavirus (SARS-CoV-2).
    Wang M; Zhang N
    Future Microbiol; 2020 Jul; 15():905-918. PubMed ID: 32524843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future.
    Li JY; You Z; Wang Q; Zhou ZJ; Qiu Y; Luo R; Ge XY
    Microbes Infect; 2020 Mar; 22(2):80-85. PubMed ID: 32087334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
    Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
    Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responding to Covid-19 - A Once-in-a-Century Pandemic?
    Gates B
    N Engl J Med; 2020 Apr; 382(18):1677-1679. PubMed ID: 32109012
    [No Abstract]   [Full Text] [Related]  

  • 7. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm.
    Bassetti M; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Mar; 50(3):e13209. PubMed ID: 32003000
    [No Abstract]   [Full Text] [Related]  

  • 8. Curing COVID-19.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2020 Oct; 20(10):1101. PubMed ID: 32919520
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].
    Ladoux A; Azoulay S; Dani C
    Med Sci (Paris); 2020; 36(6-7):555-558. PubMed ID: 32558640
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of Coronavirus and SARS-CoV-2.
    Malik YA
    Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of a novel human coronavirus threatening human health.
    Poon LLM; Peiris M
    Nat Med; 2020 Mar; 26(3):317-319. PubMed ID: 32108160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy.
    Stringer KA; Puskarich MA; Kenes MT; Dickson RP
    Pharmacotherapy; 2020 May; 40(5):382-386. PubMed ID: 32267979
    [No Abstract]   [Full Text] [Related]  

  • 15. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
    Sargin G; Yavaşoğlu Sİ; Yavasoglu I
    Med Hypotheses; 2020 Jul; 140():109756. PubMed ID: 32344306
    [No Abstract]   [Full Text] [Related]  

  • 16. SARS-CoV-2: What do we know so far?
    Khedkar PH; Patzak A
    Acta Physiol (Oxf); 2020 Jun; 229(2):e13470. PubMed ID: 32220035
    [No Abstract]   [Full Text] [Related]  

  • 17. Three months of COVID-19: A systematic review and meta-analysis.
    Rafiq D; Batool A; Bazaz MA
    Rev Med Virol; 2020 Jul; 30(4):e2113. PubMed ID: 32420674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
    Jensen JD; Lynch M
    Heredity (Edinb); 2020 May; 124(5):619-620. PubMed ID: 32251365
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxychloroquine in Covid-19: Does the end justify the means?
    Yakoub-Agha I
    Curr Res Transl Med; 2020 Aug; 68(3):81-82. PubMed ID: 32340837
    [No Abstract]   [Full Text] [Related]  

  • 20. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.
    Panera N; Tozzi AE; Alisi A
    Drugs; 2020 Jul; 80(10):941-946. PubMed ID: 32451923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.